Leukemia, myeloid, accelerated-phase
diseaseOn this page
Also known as Accelerated Phase Chronic Granulocytic LeukaemiaAccelerated Phase Chronic Myelocytic LeukaemiaAccelerated Phase Chronic Myelogenous LeukaemiaAccelerated Phase Chronic Myeloid LeukaemiaAccelerated phase chronic myeloid leukemiaAggressive-Phase Chronic Myelocytic LeukaemiaAggressive-Phase Chronic Myelogenous LeukaemiaAggressive-Phase Chronic Myeloid LeukaemiaCML ACCELERATEDCML AGGRESSIVELeukemia, Myelogenous, Aggressive PhaseLeukemia, Myelogenous, Aggressive-PhaseLeukemia, Myeloid, Accelerated PhaseLeukemia, Myeloid, Aggressive-PhaseMyelogenous Leukemia, Chronic, Aggressive PhaseMyelogenous Leukemia, Chronic, Aggressive-PhaseMyeloid Leukemia, Chronic, Accelerated PhaseMyeloid Leukemia, Chronic, Accelerated-PhaseMyeloid Leukemia, Chronic, Aggressive PhaseMyeloid Leukemia, Chronic, Aggressive-Phase
Summary
Leukemia, myeloid, accelerated-phase (MONDO:0021367) is a cancer and 7 clinical trials. Top therapeutic interventions include dasatinib anhydrous, imatinib, and nilotinib. A subtype of chronic myeloid leukemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 7
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | leukemia, myeloid, accelerated-phase |
| Mondo ID | MONDO:0021367 |
| MeSH | D015465 |
| NCIT | C3173 |
| UMLS | C0023472 |
| MedGen | 6059 |
| GARD | 0025315 |
| Is cancer (heuristic) | yes |
Also known as: Accelerated Phase Chronic Granulocytic Leukaemia · Accelerated Phase Chronic Myelocytic Leukaemia · Accelerated Phase Chronic Myelogenous Leukaemia · Accelerated Phase Chronic Myeloid Leukaemia · Accelerated phase chronic myeloid leukaemia · Accelerated phase chronic myeloid leukemia · Aggressive-Phase Chronic Myelocytic Leukaemia · Aggressive-Phase Chronic Myelogenous Leukaemia · Aggressive-Phase Chronic Myeloid Leukaemia · CML ACCELERATED · CML AGGRESSIVE · Leukemia, Myelogenous, Aggressive Phase · Leukemia, Myelogenous, Aggressive-Phase · Leukemia, Myeloid, Accelerated Phase · Leukemia, Myeloid, Aggressive-Phase · Myelogenous Leukemia, Chronic, Aggressive Phase · Myelogenous Leukemia, Chronic, Aggressive-Phase · Myeloid Leukemia, Chronic, Accelerated Phase · Myeloid Leukemia, Chronic, Accelerated-Phase · Myeloid Leukemia, Chronic, Aggressive Phase (+1 more)
Disease family
This is a subtype of chronic myeloid leukemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › leukemia › myeloid leukemia › chronic myeloid leukemia › leukemia, myeloid, accelerated-phase
Related subtypes (2): blast phase chronic myelogenous leukemia, BCR-ABL1 positive, familial chronic myelocytic leukemia-like syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 7.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE1/PHASE2 | 2 |
| PHASE3 | 1 |
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00123487 | PHASE3 | COMPLETED | Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML |
| NCT03934372 | PHASE1/PHASE2 | RECRUITING | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors |
| NCT00114959 | PHASE2 | TERMINATED | Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) |
| NCT01488253 | PHASE2 | TERMINATED | Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants |
| NCT01914484 | PHASE1/PHASE2 | COMPLETED | Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia |
| NCT00907517 | PHASE1 | TERMINATED | Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247) |
| NCT01761695 | Not specified | TERMINATED | Chronic Myelod Leukemia Registry at Asan Medical Center |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DASATINIB ANHYDROUS | 4 | 2 |
| IMATINIB | 4 | 1 |
| NILOTINIB | 4 | 1 |
| OMACETAXINE MEPESUCCINATE | 4 | 1 |
| PONATINIB | 4 | 1 |
| SCH-900776 | 2 | 1 |
| CHEMBL4583196 | 0 | 1 |
| CHEMBL3774735 | 0 | 1 |
| CHEMBL4637163 | 0 | 1 |
| CHEMBL1171086 | 0 | 1 |
| CHEMBL4519289 | 0 | 1 |
Related Atlas pages
- Drugs: Dasatinib, Imatinib, Nilotinib, Omacetaxine Mepesuccinate, Ponatinib